State-of-the-Art PaperCurrent Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data
Under an Elsevier user license
open archive
Key Words
evidence-based treatment
heart failure
pharmacological treatment
renal insufficiency
Abbreviations and Acronyms
ACEi
angiotensin-converting enzyme inhibitor
ARB
angiotensin II receptor blocker
CKD
chronic kidney disease
CRT
cardiac resynchronization therapy
CV
cardiovascular
eGFR
estimated glomerular filtration rate
ICD
implantable cardioverter defibrillator
HF
heart failure
H-ISDN
hydralazine and isosorbide-dinitrate
HFPEF
heart failure with preserved ejection fraction
HFREF
heart failure with reduced ejection fraction
KDOQI
Kidney Disease Outcomes Quality Initiative
LV
left ventricular
MRA
mineralocorticoid receptor antagonist
MI
myocardial infarction
sCr
serum creatinine
WRF
worsening renal function
Cited by (0)
Dr. Damman is supported by the Netherlands Heart Institute (ICIN) and European Society of Cardiology Heart Failure Association Research Grant. Dr. Felker has received grant support from and consulted for Novartis, Amgen, Roche Diagnostics, and Otsuka. Dr. Zannad has served on the steering committees of Pfizer, Bayer, Janssen, and Takeda; and the advisory boards of Novartis, Servier, and CardioRenal Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.